Head of the Department Mikheil Baramia, MD, PhD
Department of Radiation Oncology provides external beam radiotherapy (3DCRT, IMRT, RapidArc) and a stereotactic radiosurgery/ stereotactic body radiotherapy of the malignant tumors of brain, prostate, pelvic organs, GI tract, breast, lung, brain and bone metastasis.
The Department of Radiation Oncology is committed to obtaining the latest technology to provide highly individualized treatment for our patients. It is equipped with 2 medical linear accelerator – TrueBeam, radiosurgical system EDGE (VARIAN). Georgia is the first country among the Eastern Europe and SIS countries where this unique system is operating. It should be noted that Edge is functioning only in some advanced clinics of Europe and the U.S.A With the Edge system our clinic is able to treat more patients because of the speed, precision, and streamlined treatment planning developed in its architecture. It provides a turn-key solution for delivering full-body radiosurgery treatments with accuracy. Edge offers advanced tools designed to deliver highly conformal dose distributions to tumors of the lung, brain, spine, and other areas of the body where radiation is indicated. It is delivering high doses in a small number of fractions. These integrates and synchronizes performance of imaging and treatment technology, allowing faster and more precise image-guided radiotherapy.
This new technology was engineered from the ground up to deliver higher doses of radiation with increased accuracy, empowering the equipment to narrowly target tumors and avoid the surrounding healthy tissues and organs. TrueBeam enables faster radiotherapy treatments that are easier for the patient, who does not need to hold still for long periods of time.
EDGE and TrueBeam offers treatment options for patients who otherwise may not have been candidates for traditional radiotherapy, and offers physicians more options for treating complex cancer cases. This equipment provides breath synchronized radiotherapy which gives the opportunity to clinicians to correlate tumor position in relation to the patient’s respiratory cycle and allows for patient specific treatment margins, rather than population-based margins and it may facilitate in dose escalation.